Portada›Martes 9 de septiembre de 2025

Biomédicas del NASDAQ ante la SEC, martes 9 de septiembre de 2025

Los 26 documentos que 24 empresas del sector presentaron ante la SEC ese día, agrupados por tipo y con el enlace al original en EDGAR.

← lunes 8 de septiembre de 2025 · miércoles 10 de septiembre de 2025 →

¿Lo quieres en tu correo cada mañana, y solo de tus empresas? Crear una cuenta.

Emisiones y dilución

1. ACTUACTUATE THERAPEUTICS, INC.424B5Nueva emisión de acciones con precioEDGAR
   En el documentoDuda sustancial sobre la continuidad de la empresatexto original ▸

   …objectives of our management for future operations; · future results of anticipated product development efforts; · our ability to fund development activities, including because our financial condition raises substantial doubt as to our ability to continue as a going concern and we will require substantial additional capital to finance our operations; and · our ability to comply with evolving legal standards and regulations, particularly concerning requirements for being…
2. AMLXAmylyx Pharmaceuticals, Inc.424B5Nueva emisión de acciones con precioEDGAR
3. EDSAEdesa Biotech, Inc.424B5Nueva emisión de acciones con precioEDGAR
   En el documentoPrograma de venta continua de acciones (ATM)texto original ▸

   424B5 1 f424b5_081325.htm 424B5 Filed Pursuant to Rule 424(b)(5) Registration No. 333-288966 PROSPECTUS SUPPLEMENT (To Prospectus dated September 9, 2025) Up to $4,006,544 Common Shares We have entered into an At The Market Offering Agreement dated October 4, 2024 (the “Sales Agreement”) with H.C. Wainwright & Co., LLC (“Wainwright” or the “Sales Agent”), relating to our common shares, no par value (“common shares”), offered by this…
4. EQEquillium, Inc.S-3Capacidad de emisión registradaEDGAR
5. HRTXHERON THERAPEUTICS, INC. /DE/S-3Capacidad de emisión registradaEDGAR
6. HRTXHERON THERAPEUTICS, INC. /DE/S-3Capacidad de emisión registradaEDGAR
7. TCRTAlaunos Therapeutics, Inc.S-3/ACapacidad de emisión registrada (enmienda)EDGAR

Participaciones y control

1. APLMApollomics Inc.SC 13DCambio en participación significativaEDGAR
2. VORVor Biopharma Inc.SC 13D/ACambio en participación significativaEDGAR

Informes y hechos relevantes

1. NXTSNexentis Technologies Inc.8-KNuevo acuerdo materialEDGAR
   En el documentoContrasplit de accionestexto original ▸

   …on July 3, 2024, at the special meeting of stockholders of the Company held on June 28, 2024, the holders of approximately 88.61% of the Company’s voting power entitled to vote at that special meeting, approved to effect a reverse stock split of the issued and outstanding shares of the Company’s common stock, $0.0001 par value per share (the “Common Stock”), by a ratio of no less than 1-for-2 and not more than 1-for-35, with the exact split…
2. RNTXRein Therapeutics, Inc.8-KVenta de acciones no registrada (colocación privada)EDGAR
3. AVBPArriVent BioPharma, Inc.8-KOtros hechos relevantesEDGAR
4. BIAFbioAffinity Technologies, Inc.8-KOtros hechos relevantesEDGAR
5. CURXCuranex Pharmaceuticals Inc10-QInforme trimestralEDGAR
   En el documentoDuda sustancial sobre la continuidad de la empresatexto original ▸

   …operations, anticipates further losses, has negative cash flows from operating activities, and is dependent on future issuances of equity or other financing to fund ongoing operations. These factors raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying financial statements do not include any adjustments to the reported carrying values of assets and liabilities, reported revenues and expenses, or classifications in the statements of…

   En el documentoContrasplit de accionestexto original ▸

   …000 shares of common stock at par value. No shares of common stock were issued during the three and six months ended June 30, 2025 Reverse Stock Split Effective November 19, 2024, the Board of Directors approved a three-for-five reverse stock split of the Company’s issued and outstanding shares of common stock for shareholders of record as of the same date. The par value of $0.0001 per share remains unchanged. As a result of the reverse stock split…
6. DCOYDecoy Therapeutics Inc.8-KOtros hechos relevantesEDGAR
7. EDSAEdesa Biotech, Inc.8-KOtros hechos relevantesEDGAR
8. ELUTELUTIA INC.8-KNuevo acuerdo materialEDGAR
9. HROWHARROW, INC.8-KOtros hechos relevantesEDGAR
10. JBIOJade Biosciences, Inc.8-KCambio en el consejo o la direcciónEDGAR
11. REVBREVELATION BIOSCIENCES, INC.8-KOtros hechos relevantesEDGAR
12. TELOTelomir Pharmaceuticals, Inc.8-KOtros hechos relevantesEDGAR
13. TENXTENAX THERAPEUTICS, INC.8-KNuevo acuerdo materialEDGAR
14. XCUREXICURE, INC.8-KCambio en el consejo o la direcciónEDGAR
15. XLOXilio Therapeutics, Inc.8-KOtros hechos relevantesEDGAR

Juntas de accionistas

1. INTSINTENSITY THERAPEUTICS, INC.DEF 14AConvocatoria de junta de accionistasEDGAR
2. TLPHTALPHERA, INC.DEF 14AConvocatoria de junta de accionistasEDGAR
   En el documentoDuda sustancial sobre la continuidad de la empresatexto original ▸

   …opinion or disclaimer of opinion and was not qualified or modified as to uncertainty, audit scope, or accounting principles, except for the following: the report included an explanatory paragraph regarding substantial doubt about our ability to continue as a going concern as result of its recurring operating losses and negative operating cash flows. Withum’s audit report on our financial statements for the year ended December 31, 2021, did not contain any adverse opinion…

← lunes 8 de septiembre de 2025 · miércoles 10 de septiembre de 2025 →

Esto mismo, cada mañana y solo de tus empresas. Sigue a las que te interesen y recibe en tu correo lo que presenten ante la SEC, en castellano. Crear una cuenta. ¿Ya tienes cuenta? Entrar.

Esto no son recomendaciones de inversión. Son hechos públicos verificables en su fuente. Lee siempre el documento original antes de decidir nada. Aviso legal.